Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism - PubMed

Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism

S HERTZ et al. J Am Med Assoc. 1946.

Similar articles

• The treatment of hyperthyroidism with radioactive iodine.

  CHAPMAN EM, EVANS RD. CHAPMAN EM, et al. J Am Med Assoc. 1946 May 11;131:86-91. doi: 10.1001/jama.1946.02870190010003. J Am Med Assoc. 1946. PMID: 21025610 No abstract available.

• Use of radioactive iodine in the treatment of hyperthyroidism.

  ALDERMAN AM. ALDERMAN AM. J Bowman Gray Sch Med Wake For Coll. 1947 Jan;5(1):15-7. J Bowman Gray Sch Med Wake For Coll. 1947. PMID: 20287089 No abstract available.

• [Iodine and thyroid gland with or without nuclear catastrophe].

  Dilas LT, Bajkin I, Icin T, Paro JN, Zavisić BK. Dilas LT, et al. Med Pregl. 2012 Nov-Dec;65(11-12):489-95. doi: 10.2298/mpns1212489t. Med Pregl. 2012. PMID: 23297615 Review. Serbian.

• A review of psychoendocrine research on the pituitary-thyroid system.

  Mason JW. Mason JW. Psychosom Med. 1968 Sep-Oct;30(5):Suppl:666-81. doi: 10.1097/00006842-196809000-00024. Psychosom Med. 1968. PMID: 4179122 Review. No abstract available.

Cited by

• Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?

  Dondi F, Miceli A, Rovera G, Feudo V, Battisti C, Rondini M, Marongiu A, Mura A, Camedda R, De Feo MS, Conte M, Gorica J, Ferrari C, Nappi AG, Santo G. Dondi F, et al. Bioengineering (Basel). 2024 Jul 14;11(7):714. doi: 10.3390/bioengineering11070714. Bioengineering (Basel). 2024. PMID: 39061796 Free PMC article. Review.

• Radiopharmaceutical good practices: Regulation between hospital and industry.

  Faivre-Chauvet A, Bourdeau C, Bourgeois M. Faivre-Chauvet A, et al. Front Nucl Med. 2022 Sep 7;2:990330. doi: 10.3389/fnume.2022.990330. eCollection 2022. Front Nucl Med. 2022. PMID: 39354961 Free PMC article.

• Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies.

  Abou DS, Zerkel P, Robben J, McLaughlin M, Hazlehurst T, Morse D, Wadas TJ, Pandya DN, Oyama R, Gaehle G, Nickels ML, Thorek DLJ. Abou DS, et al. Cancer Biother Radiopharm. 2022 Jun;37(5):355-363. doi: 10.1089/cbr.2022.0010. Cancer Biother Radiopharm. 2022. PMID: 35695807 Free PMC article.

• Advances in Functional Imaging of Differentiated Thyroid Cancer.

  Klain M, Zampella E, Nappi C, Nicolai E, Ambrosio R, Califaretti E, Lamartina L, Schlumberger M, Deandreis D, Salvatore D, Cuocolo A. Klain M, et al. Cancers (Basel). 2021 Sep 23;13(19):4748. doi: 10.3390/cancers13194748. Cancers (Basel). 2021. PMID: 34638232 Free PMC article. Review.

• Advances in Radioligand Theranostics in Oncology.

  Lawal IO, Abubakar SO, Ndlovu H, Mokoala KMG, More SS, Sathekge MM. Lawal IO, et al. Mol Diagn Ther. 2024 May;28(3):265-289. doi: 10.1007/s40291-024-00702-4. Epub 2024 Mar 31. Mol Diagn Ther. 2024. PMID: 38555542 Review.

MeSH terms

Substances